Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Post Q2 2025 Earnings of $0.57 Per Share, Zacks Research Forecasts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Wednesday, April 17th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.57 per share for the quarter, up from their previous forecast of $0.56. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The firm had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion.

A number of other research analysts have also weighed in on the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a report on Friday, March 8th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their target price for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Finally, Barclays upped their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $13.78.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $12.78 on Thursday. The firm’s 50 day simple moving average is $13.47 and its 200-day simple moving average is $11.22. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $14.47. The stock has a market capitalization of $14.33 billion, a price-to-earnings ratio of -27.19, a PEG ratio of 1.57 and a beta of 1.05. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TEVA. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 5.5% in the 4th quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 19,315 shares of the company’s stock worth $176,000 after purchasing an additional 1,000 shares during the last quarter. US Bancorp DE lifted its holdings in Teva Pharmaceutical Industries by 36.5% during the fourth quarter. US Bancorp DE now owns 3,828 shares of the company’s stock worth $40,000 after acquiring an additional 1,023 shares in the last quarter. Desjardins Global Asset Management Inc. lifted its holdings in Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after acquiring an additional 1,070 shares in the last quarter. Marshall Wace LLP lifted its holdings in Teva Pharmaceutical Industries by 2.7% during the fourth quarter. Marshall Wace LLP now owns 48,771 shares of the company’s stock worth $445,000 after acquiring an additional 1,273 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock worth $688,000 after acquiring an additional 1,375 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the transaction, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares of the company’s stock, valued at approximately $13.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at $132,062.12. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock valued at $5,132,766 over the last quarter. Insiders own 0.62% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.